Imipramine
Brand names: Tofranil
Imipramine is a tricyclic antidepressant used in the treatment of depression and also for nocturnal enuresis in children.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits the reuptake of noradrenaline and serotonin at the synaptic cleft and also has antimuscarinic, antihistaminic and alpha-adrenergic blocking actions.
Prescribing in practice
- Tricyclic antidepressants are dangerous in overdose, causing cardiac arrhythmias, seizures and coma, so consider toxicity risk in patients at risk of self-harm and limit quantities supplied.
- Antimuscarinic and cardiovascular effects make it unsuitable in recent myocardial infarction, arrhythmias and severe cardiac disease, and it should be used with caution in the elderly.
- When used for enuresis in children, dosing must follow a children's formulary and avoid the doses used for depression.
Monitoring
Monitor mood, suicidal ideation (particularly early in treatment and in younger patients), cardiac status and antimuscarinic side effects.
Counselling the patient
- Explain that full antidepressant benefit may take several weeks.
- Do not stop the medicine abruptly, as withdrawal effects can occur.
- Report worsening mood, suicidal thoughts, palpitations or difficulty passing urine.
Evidence & guidelines
Imipramine is one of the original tricyclic antidepressants with long-established efficacy in depression; NICE recommends caution owing to its toxicity in overdose relative to newer agents.
Reference: NICE CG111 (Nocturnal Enuresis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185